UBS Initiates Coverage On Bioage Labs with Neutral Rating, Announces Price Target of $8

Benzinga Newsdesk www.benzinga.com Neutral 82.3%

Neg 0% Neu 82.3% Pos 0%

UBS analyst Alice Nettleton initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Neutral rating and announces Price Target of $8.